Medcube Limited 08888419 false 2023-01-01 2023-12-31 2023-12-31 The principal activity of the company is performing the function of a holding company. Digita Accounts Production Advanced 6.30.9574.0 true 08888419 2023-01-01 2023-12-31 08888419 2023-12-31 08888419 bus:OrdinaryShareClass1 2023-12-31 08888419 bus:OrdinaryShareClass2 2023-12-31 08888419 bus:OrdinaryShareClass3 2023-12-31 08888419 core:FinancialAssetsCostLessImpairment core:Non-currentFinancialInstruments 2023-12-31 08888419 core:CurrentFinancialInstruments 2023-12-31 08888419 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 08888419 core:Non-currentFinancialInstruments 2023-12-31 08888419 core:Non-currentFinancialInstruments core:AfterOneYear 2023-12-31 08888419 bus:SmallEntities 2023-01-01 2023-12-31 08888419 bus:AuditExemptWithAccountantsReport 2023-01-01 2023-12-31 08888419 bus:FullAccounts 2023-01-01 2023-12-31 08888419 bus:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 08888419 bus:RegisteredOffice 2023-01-01 2023-12-31 08888419 bus:Director1 2023-01-01 2023-12-31 08888419 bus:Director2 2023-01-01 2023-12-31 08888419 bus:Director3 2023-01-01 2023-12-31 08888419 bus:Director4 2023-01-01 2023-12-31 08888419 bus:Director5 2023-01-01 2023-12-31 08888419 bus:Director6 2023-01-01 2023-12-31 08888419 bus:OrdinaryShareClass1 2023-01-01 2023-12-31 08888419 bus:OrdinaryShareClass2 2023-01-01 2023-12-31 08888419 bus:OrdinaryShareClass3 2023-01-01 2023-12-31 08888419 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 08888419 countries:AllCountries 2023-01-01 2023-12-31 08888419 2022-01-01 2022-12-31 08888419 2022-12-31 08888419 bus:OrdinaryShareClass1 2022-12-31 08888419 bus:OrdinaryShareClass2 2022-12-31 08888419 bus:OrdinaryShareClass3 2022-12-31 08888419 core:CurrentFinancialInstruments 2022-12-31 08888419 core:CurrentFinancialInstruments core:WithinOneYear 2022-12-31 08888419 core:Non-currentFinancialInstruments 2022-12-31 08888419 core:Non-currentFinancialInstruments core:AfterOneYear 2022-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 08888419

Medcube Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 December 2023

 

Medcube Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 7

 

Medcube Limited

Company Information

Directors

Mr Geoffroy Berbesson

Mr Thomas Joly

Mr Franck Legoux

Mr Bertrand Pivin

Dealbydeal Invest

Mr Thierry Degroote

Registered office

5 Fleet Place
London
EC4M 7RD

Accountants

1Office Group Ltd
65 London Wall
London
EC2M 5TU

 

Medcube Limited

(Registration number: 08888419)
Balance Sheet as at 31 December 2023

Note

2023

2022

Fixed assets

 

Other financial assets

4

20,000

20,000

Current assets

 

Debtors

5

7,568,000

6,818,000

Cash at bank and in hand

 

3,261

166,301

 

7,571,261

6,984,301

Creditors: Amounts falling due within one year

6

(1,523)

(1,286)

Net current assets

 

7,569,738

6,983,015

Total assets less current liabilities

 

7,589,738

7,003,015

Creditors: Amounts falling due after more than one year

6

(1,500,932)

(660,000)

Net assets

 

6,088,806

6,343,015

Capital and reserves

 

Called up share capital

7

1,159,056

1,159,056

Share premium reserve

6,558,011

6,558,011

Capital redemption reserve

(23,451)

(23,451)

Retained earnings

(1,604,810)

(1,350,601)

Shareholders' funds

 

6,088,806

6,343,015

For the financial year ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the Board on 29 August 2024 and signed on its behalf by:
 

 

Medcube Limited

(Registration number: 08888419)
Balance Sheet as at 31 December 2023

.........................................
Mr Thomas Joly
Director

.........................................
Mr Franck Legoux
Director

 

Medcube Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
5 Fleet Place
London
EC4M 7RD

These financial statements were authorised for issue by the Board on 29 August 2024.

2

Accounting policies

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The functional and presentational currency of the financial statements is euros (€).


Going Concern
The accounts have been prepared on a going concern basis.

The directors, having made such enquiries as they considered appropriate and having a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future, have prepared the financial statements on a going concern basis. The financial statements do not include any adjustments that would result from withdrawal of this support.
 


Covid-19
Covid-19 is not expected to have a significant impact on the entity. Management has determined that there is no
material uncertainty that casts doubt on the entity’s ability to continue as a going concern. It expects that
Covid-19 might have some impact, though not significant, for example, in relation to expected future
performance, or the effects on some future asset valuations.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

 

Medcube Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Financial instruments

Recognition and measurement
Financial instruments have been recorded at transaction price / historical cost, less impairment.
 

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 6 (2022 - 6).

 

Medcube Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

4

Other financial assets (current and non-current)

Financial assets at cost less impairment

Total

Non-current financial assets

Cost or valuation

At 1 January 2023

20,000

20,000

At 31 December 2023

20,000

20,000

Impairment

Carrying amount

At 31 December 2023

20,000

20,000

5

Debtors

Current

2023

2022

Other debtors

7,568,000

6,818,000

6

Creditors

Creditors: amounts falling due within one year

2023

2022

Due within one year

Accruals

1,523

1,286

Creditors: amounts falling due after more than one year

Note

2023

2022

Due after one year

 

Loans and borrowings

8

1,500,932

660,000

 

Medcube Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

7

Share capital

Allotted, called up and fully paid shares

 

2023

2022

 

No.

No.

Ordinary shares of €1 each

406,762

406,762

406,762

406,762

B Ordinary shares of €1 each

744,557

744,557

744,557

744,557

C Ordinary shares of €1 each

7,737

7,737

7,737

7,737

 

1,159,056

1,159,056

1,159,056

1,159,056

8

Loans and borrowings

2023

2022

Non-current loans and borrowings

Other borrowings

1,500,932

660,000